Adjuvanted pandemic influenza candidate vaccine — Competitive Intelligence Brief

Adjuvanted pandemic influenza candidate vaccine (Adjuvanted pandemic influenza candidate vaccine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adjuvanted inactivated influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Adjuvanted inactivated influenza vaccine Immunology / Infectious Disease Biologic

Target snapshot

Adjuvanted pandemic influenza candidate vaccine (Adjuvanted pandemic influenza candidate vaccine) — GlaxoSmithKline. This vaccine stimulates the immune system to recognize and respond to pandemic influenza virus antigens, with an adjuvant component to enhance the immune response.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adjuvanted pandemic influenza candidate vaccine TARGET	Adjuvanted pandemic influenza candidate vaccine	GlaxoSmithKline	phase 3	Adjuvanted inactivated influenza vaccine
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adjuvanted inactivated influenza vaccine class)

1. GlaxoSmithKline · 1 drug in this class
2. University of British Columbia · 1 drug in this class